The role of glutathione in brain tumor drug resistance

详细信息	查看全文 | 推荐本文 |

• 作者：Donald S. Backos^a ; Christopher C. Franklin^a ; ^b ; Philip Reigan^a ; ^b ; ^{philip.reigan@ucdenver.edu}
• 关键词：GSH ; glutathione ; GCL ; glutamate cysteine ligase ; GS ; glutathione synthetase ; GPx ; glutathione peroxidase ; GR ; glutathione reductase ; GST ; glutathione-S-transferase ; ROS ; reactive oxygen species ; Mrp ; multidrug resistance-associated protein ; 纬-GC ; 纬-glu
• 刊名：Biochemical Pharmacology
• 出版年：2012
• 期刊代码：2_00062952
• 类别：pha
• 出版时间：15 April, 2012
• 卷：83
• 期：8
• 页码：1005-1012
• 文件大小：525 K

摘要

Chemotherapy is central to the current treatment modality for primary human brain tumors, but despite high-dose and intensive treatment regimens there has been little improvement in patient outcome. The development of tumor chemoresistance has been proposed as a major contributor to this lack of response. While there have been some improvements in our understanding of the molecular mechanisms underlying brain tumor drug resistance over the past decade, the contribution of glutathione (GSH) and the GSH-related enzymes to drug resistance in brain tumors have been largely overlooked. GSH constitutes a major antioxidant defense system in the brain and together with the GSH-related enzymes plays an important role in protecting cells against free radical damage and dictating tumor cell response to adjuvant cancer therapies, including irradiation and chemotherapy. Glutamate cysteine ligase (GCL), glutathione synthetase (GS), glutathione peroxidase (GPx), glutathione reductase (GR), glutathione-S-transferases (GST), and GSH complex export transporters (GS-X pumps) are major components of the GSH-dependent enzyme system that function in a dynamic cascade to maintain redox homeostasis. In many tumors, the GSH system is often dysregulated, resulting in a more drug resistant phenotype. This is commonly associated with GST-mediated GSH conjugation of various anticancer agents leading to the formation of less toxic GSH-drug complexes, which can be readily exported from the cell. Advances in our understanding of the mechanisms of drug resistance and patient selection based on biomarker profiles will be crucial to adapt therapeutic strategies and improve outcomes for patients with primary malignant brain tumors.